(Q48955149)

17 February 2018

title

Provider incentives and prescribing behavior in Europe. (English)

1 reference

17 February 2018

3

Caroline Rudisill

1 reference

17 February 2018

author name string

Elias Mossialos

series ordinal

1

1 reference

17 February 2018

Tom Walley

series ordinal

2

1 reference

17 February 2018

publication date

1 February 2005

1 reference

17 February 2018

Expert Review of Pharmacoeconomics & Outcomes Research

published in

1 reference

17 February 2018

volume

5

1 reference

17 February 2018

issue

1

1 reference

17 February 2018

page(s)

81-93

1 reference

17 February 2018

Effects of financial incentives on medical practice: results from a systematic review of the literature and methodological issues

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737167.5.1.81

Pharmaceutical expenditure in Spain: cost and control

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.5.1.81

What can PACT tell us about prescribing in general practice?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.5.1.81

Fundholders' prescribing costs: the first five years

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.5.1.81

The threat of 'cream skimming' in the post-reform NHS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.5.1.81

The effect of fundholding on prescribing and referral costs: a review of the evidence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.5.1.81

Motivating general practitioners to change their prescribing: the incentive of working together.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.5.1.81

Prescribing incentive schemes in two NHS regions: cross sectional survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.5.1.81

Importing budget systems from other countries: what can we learn from the German drug budget and the British GP fundholding?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.5.1.81

Using disease management and market reforms to address the adverse economic effects of drug budgets and price and reimbursement regulations in Germany

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.5.1.81

The new pharmaceutical policy in Italy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.5.1.81

Primary care physicians' experience of financial incentives in managed-care systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.5.1.81

Physicians' ethical beliefs about cost-control arrangements

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.5.1.81

How are primary care organizations using financial incentives to influence prescribing?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.5.1.81

Despite Financial Penalties, French Physicians' Knowledge of Regulatory Practice Guidelines Is Poor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.5.1.81

FROM CLINICAL RECOMMENDATIONS TO MANDATORY PRACTICE The Introduction of Regulatory Practice Guidelines in the French Healthcare System

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.5.1.81

Consequences of implementing a drug budget for office-based physicians in Germany

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737167.5.1.81

21 January 2018

Identifiers

DOI

10.1586/14737167.5.1.81

1 reference

17 February 2018

1 reference

17 February 2018